Evidence map›Paper›PMID 42425092›Full record

ArticleStem cell reports2026

Induction of human pruriceptors from pluripotent stem cells via transcription factors.

Hisato Iriki, Ruiqi Hu, Xu Li, Erdene Baljinnyam, Carina Habich, Ichiro Imanishi, Loan N Miller, Kavya Chegireddy, Laraib Iqbal Malik, Daniel Yassky and 7 more

Abstract read
In one paragraph

Article in Stem cell reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors.

Hisato IrikiKimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Mark Lebwohl Center for Neuroinflammation and Sensation, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Ruiqi HuNash Family Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Stem Cell Biology and Regenerative Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Xu LiKimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Mark Lebwohl Center for Neuroinflammation and Sensation, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Erdene BaljinnyamDepartment of Stem Cell Biology and Regenerative Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Carina HabichAbbVie Deutschland GmbH & Co KG, Neuroscience Discovery, Knollstrasse, Ludwigshafen am Rhein, Germany.
Ichiro ImanishiKimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Loan N MillerAbbVie Inc., North Chicago, IL, USA.
Kavya ChegireddyAbbVie Cambridge Research Center, Cambridge, MA, USA.
Laraib Iqbal MalikAbbVie Cambridge Research Center, Cambridge, MA, USA.
Daniel YasskyKimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Raphael KüblerNash Family Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Aaron Ver HeulSanofi, Immunology and Inflammation Therapeutic Area, Cambridge, MA, USA.
Kathleen M SmithAbbVie Cambridge Research Center, Cambridge, MA, USA.
Peter ReinhardtAbbVie Deutschland GmbH & Co KG, Neuroscience Discovery, Knollstrasse, Ludwigshafen am Rhein, Germany.
Eric R GoedkenAbbVie Cambridge Research Center, Cambridge, MA, USA.
Brian S KimKimberly and Eric J. Waldman Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Mark Lebwohl Center for Neuroinflammation and Sensation, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Marc and Jennifer Lipschultz Precision Immunology Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Nash Family Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Allen Discovery Center for Neuroimmune Interactions, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Samuele G MarroNash Family Department of Neuroscience, Friedman Brain Institute, Icahn School of Medicine at Mount Sinai, New York, NY, USA; Department of Stem Cell Biology and Regenerative Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: samuele.marro@mssm.edu.

Funding

Role of POU4F1 in a Novel Form of AtaxiaR21NS130319 · NINDS · UNIVERSITY OF WISCONSIN-MADISON · PI MARRO, SAMUELE G., WEBB, BRYN D · 2023 to 2024
$464k
NINDS NIH HHS R21 NS130319
6 · The paper itself

Abstract

Pruriception is crucial for defense against external stimuli but can lead to chronic pruritus, a debilitating condition affecting millions worldwide. Our understanding of the cellular and molecular mechanisms behind the sensation of itch has been hindered by the lack of functional human models. Here, we address this limitation by developing a protocol to generate induced pruriceptors (iPruriceptors) from human-induced pluripotent stem cells (iPSCs). We compared two differentiation approaches: a direct method via forced expression of transcription factors (TFs) in iPSCs and a 2-step process through expression of TFs in iPSC-derived neural crest cells (NCCs). The 2-step protocol proved superior in inducing a transcriptional program enriched for features of human pruriceptors. Our optimized protocol employs forced expression of NGN1 and ISL1 to drive differentiation from NCCs into pruriceptors, enhancing the expression of known pruritogen receptors such as IL31RA, which pairs with OSMR, and HRH1. The induction of this transcriptional program leads to functional maturation of iPruriceptors. Accordingly, iPruriceptors exhibit robust responses to itch stimuli and in vivo-like itch pharmacology such as treatment with ABT-317, a JAK1 inhibitor tool compound, similar to those targeting intensive pruritus in atopic dermatitis (AD). Importantly, iPruriceptors can be generated without viral vectors or safe-harbor gene editing, using a PiggyBac-based transfection method that simplifies scalability. Our protocol offers a robust platform for investigating itch biology, modeling chronic pruritus, and enabling high-throughput screening for therapeutic target discovery.

Indexed as

Induced Pluripotent Stem CellsPruritusTranscription FactorsAnimalsCell DifferentiationHumansNeural CrestTranscription Factorschronic pruritusiN cellsiPruriceptorsiPSC-derived neural crest cellsiPSCsISL1itchJAK1-inhibitorNGN1pruriceptors

Identifiers

PMID42425092
PMCPMC13476876

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.